Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Nov 03 2016

• By Mandy Jackson

Related Content

Actavis will become Allergan to emphasize branded pharma focus

Feb 19 2015

Allergan Sees Growth From New Launches, Not Big M&A

Aug 09 2016

Forest gaining 'relevant' GI position with Furiex buy

Apr 29 2014

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Oct 28 2016

3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca

Oct 31 2016

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Allergan's Fishing For Deals, But Don't Expect A Big Catch

May 11 2016

Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations

Nov 01 2016

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn

Sep 21 2016

Beyond Tax Benefits: Portfolio Opportunities In A Pfizer-Allergan Deal

Nov 11 2015

Related Companies

Allergan plc

Allergan plc

Allergan plc

Forest Laboratories, Inc.

Teva Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

Rhythm Pharmaceuticals, Inc.

Additional Topics

Companies Sales & Earnings Launches Strategy Commercial BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window